Polypill approach to reduce vascular risk after stroke in Ghana
Official title: Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)
Run by Northern California Institute of Research and Education · NCT05963568 · Data updated 2026-11-12
This study tests whether taking a single daily Polycap polypill (blood-pressure meds, a statin, and aspirin) for two years helps stroke patients in Ghana reduce their risk of future vascular events compared with usual care.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Northern California Institute of Research and Education Academic / other |
| Locations | 4 sites (Parakou and 3 other locations) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | January 31, 2029 |
| Study ends | February 1, 2029 |
| Registry record updated | July 6, 2026 |
| Trial ID | NCT05963568 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who recently had an ischemic stroke (within 2 months) and have at least one risk factor such as hypertension, diabetes, or prior cardiovascular disease.
✕Probably not a fit
Patients without contraindications to the polypill or those not experiencing a risk reduction may not see benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
SMAART II is a phase 3 trial enrolling adults who recently had an ischemic stroke in several Ghanaian hospitals. The study compares daily Polycap fixed-dose therapy to standard care over 24 months, aiming to lower composite vascular risk. It uses a hybrid design to assess both efficacy and how best to implement polypill use in an under-resourced healthcare setting. Participants must meet criteria such as age over 18, ischemic stroke within 2 months, and at least one cardiovascular risk factor or comorbidity. The trial seeks to inform routine integration and policy adoption if beneficial.
Why it matters
Potential benefit: If successful, patients could experience lower risk of recurrent stroke and other vascular events through a simple, once-daily therapy.
How similar studies have gone: Prior similar polypill approaches have shown promise, but results vary by setting; SMAART II explores real-world implementation in Ghana.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Above the age of 18 years; male or female * Ischemic stroke diagnosis no greater than two months before enrollment. Ischemic strokes including� lacunar, large-vessel atherosclerotic, cardio-embolic subtypes are eligible * Subjects with stroke may present with at least one of the following additional conditions: Documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension \>140/90mmHg or previous treatment with antihypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction * Legally competent to sign informed consent. Exclusion Criteria: * Unable to sign informed consent * Contraindications to any of the components of the polypill * Hemorrhagic stroke * Severe cognitive impairment/dementia or severe global disability limiting the capacity of self-care * Severe congestive cardiac failure (NYHA III-IV) * Severe renal disease, eGFR \<30ml/min/1.73m2), renal dialysis; awaiting renal transplant or transplant recipient * Cancer diagnosis or treatment in past 2 years * Need for oral anticoagulation at the time of randomization or planned in the future months; * Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation) * Nursing/pregnant mothers * Do not agree to the filing, forwarding and use of his/her pseudonymized data.
Where it's running
-
University Teaching Hospital of Parakou
Parakou, Benin Recruiting -
University of Ilorin Teaching Hospital
Ilorin, Nigeria Recruiting -
Kwame Nkrumah Institute of Science & Technology
Kumasi, Ghana Active not recruiting -
Aga Khan Hospital
Dar es Salaam, Tanzania Not yet recruiting
Study contacts
- Study coordinator: Bruce Ovbiagele, MD
- Email: bruce.ovbiagele@va.gov
- Phone: 415-750-2047
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Web-based therapy using action observation and mirror therapy for arm weakness after stroke
This trial tests whether a mobile telerehabilitation app delivering action observation therapy (AOT) alone or combined AOT with mirror therapy (AOT-MT) can improve upper limb function in people with subacute stroke.
-
Remote Ischaemic Conditioning for Fatigue After Stroke 2
Aat least 12 weeks after stroke, adults with post-stroke fatigue will try a simple hand-arm cuff treatment at home to see if it helps reduce fatigue.
-
Dual-task balance training plus computer-based cognitive training after stroke
In adults who recently had a stroke, the study tests whether adding computerized cognitive exercises to balance training improves balance and other recovery outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.